Skip to main content

CorMedix Inc.

corporate_fare Company Profile

CorMedix Inc.

CRMD·NASDAQ·Life Sciences·CIK 0001410098

CorMedix Inc. is a biopharmaceutical company that develops and sells therapeutic products for life-threatening diseases and conditions. The company's main focus has been the commercialization of DefenCath® (taurolidine and heparin) in the U.S., which it launched in 2024 for use in hemodialysis. On August 29, 2025, CorMedix Inc. acquired Melinta Therapeutics, LLC, expanding its team and commercial platform. This acquisition increased the company's commercial portfolio with six marketed, hospital- and clinic-focused infectious disease products: REZZAYO® (rezafungin for injection), MINOCIN® (minocycline) for Injection ("MINOCIN IV"), VABOMERE® (meropenem and vaborbactam), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin), and BAXDELA® (delafloxacin). The acquisition also included TOPROL-XL® (metoprolol succinate), a cardiovascular product. The Melinta Portfolio supports a multi-channel strategy for delivering anti-infectives for serious gram-positive, gram-negative, and fungal infections within hospitals and the hospital ecosystem, including emergency departments, outpatient clinics, and home infusion care. The company's corporate strategy focuses on maximizing the value of its current portfolio, with promotional efforts concentrated on DefenCath, REZZAYO, MINOCIN IV, and VABOMERE.

CorMedix Inc. (NASDAQ:CRMD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for CRMD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for CRMD spans 4, 10-Q, 8-K.

Recent high-impact activity:

  • CEO Joseph Todisco Buys 80,000 CRMD Shares for $391,200 on the Open Market
  • CorMedix 10-Q: Material Weakness Persists as DefenCath Revenue Falls to $17.2M
  • CorMedix Q3 Revenue $54.5M Beats Consensus; Suspends 2027 DefenCath Guidance on CMS Changes
  • CorMedix Beats Q3 Revenue Estimates but Suspends 2027 DefenCath Guidance
  • CorMedix Pays $145M Cash Plus Stock for Heron Assets, Adds Four Commercial Drugs

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$311.71M
Net Income
$163.06M
Diluted EPS
$2.04
Op. Cash Flow
$175.05M
Free Cash Flow
$172.79M
Gross Profit
$275.75M
Operating Income
$150.14M
Cash & Equivalents
$144.84M
Debt / Equity
0.00×
Net Margin
52.3%
Shares Outstanding
79.26M sh
Source: 10-K · filed 2026-03-05 · accession 0001213900-26-023889

Short Interest & Short Volume

8.44 days to cover

FINRA reported short interest of 14,205,973 shares in CRMD as of the October 30, 2026 settlement, a 3.1% decrease from the prior period — about 8.4 days to cover at its recent average daily volume. On November 20, 2026, 65.4% of CRMD volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)14,205,973 shares as of October 30, 2026
Change vs prior period▼ 3.1%
Days to cover8.44 at avg daily volume of 1,683,358
Daily short volume (FINRA facilities)65.4% of 1,225,183 shares on November 20, 2026
5-day average short volume58.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$5.32 +0.95% today
52-week range · as of 2026-11-16 $4.65 – $13.02
Market cap
$419.16M
Volume
3.6M (1.8× avg)
3-mo avg 2M
Live data · 2026-11-21 08:34 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CRMD - Latest Insights

CRMD
Nov 16, 2026, 7:30 AM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $4.61
Real-time Price: $5.32 info
Change: +$0.710 (+15%) info
Market Cap: $419.163M info
CRMD
Nov 12, 2026, 8:21 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.15
Real-time Price: $5.32 info
Change: +$0.170 (+3%) info
Market Cap: $419.163M info
CRMD
Nov 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.25
Real-time Price: $5.32 info
Change: +$0.070 (+1%) info
Market Cap: $419.163M info
CRMD
Nov 12, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.25
Real-time Price: $5.32 info
Change: +$0.070 (+1%) info
Market Cap: $419.163M info
CRMD
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $5.50
Real-time Price: $5.32 info
Change: -$0.180 (-3%) info
Market Cap: $419.163M info
CRMD
Nov 02, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $5.32 info
Change: -$0.180 (-3%) info
Market Cap: $419.163M info
CRMD
Nov 02, 2026, 7:32 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.62
Real-time Price: $5.32 info
Change: -$0.2955 (-5%) info
Market Cap: $419.163M info
CRMD
Oct 19, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.45
Real-time Price: $5.32 info
Change: -$2.13 (-29%) info
Market Cap: $419.163M info
CRMD
Aug 13, 2026, 8:07 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.65
Real-time Price: $5.32 info
Change: -$2.33 (-30%) info
Market Cap: $419.163M info
CRMD
Aug 13, 2026, 7:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.65
Real-time Price: $5.32 info
Change: -$2.33 (-30%) info
Market Cap: $419.163M info
CRMD
Aug 13, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.49
Real-time Price: $5.32 info
Change: -$2.17 (-29%) info
Market Cap: $419.163M info
CRMD
Aug 07, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.45
Real-time Price: $5.32 info
Change: -$2.13 (-29%) info
Market Cap: $419.163M info
CRMD
Jul 02, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.61
Real-time Price: $5.32 info
Change: -$3.29 (-38%) info
Market Cap: $419.163M info
CRMD
Jul 01, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.51
Real-time Price: $5.32 info
Change: -$2.19 (-29%) info
Market Cap: $419.163M info
CRMD
Jun 24, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.43
Real-time Price: $5.32 info
Change: -$3.11 (-37%) info
Market Cap: $419.163M info
CRMD
Jun 08, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.44
Real-time Price: $5.32 info
Change: -$3.12 (-37%) info
Market Cap: $419.163M info
CRMD
Jun 08, 2026, 8:32 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $8.43
Real-time Price: $5.32 info
Change: -$3.11 (-37%) info
Market Cap: $419.163M info
CRMD
May 15, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $7.94
Real-time Price: $5.32 info
Change: -$2.62 (-33%) info
Market Cap: $419.163M info
CRMD
May 14, 2026, 8:00 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.77
Real-time Price: $5.32 info
Change: -$3.45 (-39%) info
Market Cap: $419.163M info
CRMD
May 14, 2026, 7:34 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.07
Real-time Price: $5.32 info
Change: -$2.75 (-34%) info
Market Cap: $419.163M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets